Biogen touted strong Q3 sales of its Alzheimer’s drug Leqembi a day after announcing a deal worth up to $1.45 billion with ...

Despite a somewhat ambling launch, Biogen’s Eisai-partnered Alzheimer’s disease drug Leqembi continues to grow. | All told, third-quarter U.S. Leqembi sales grew 33% over the prior quarter to $39 ...

Biogen Inc. raised its annual earnings guidance after reporting better-than-expected third-quarter sales and profit, driven ...

This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...

We continue to see momentum with ongoing product launches and we are increasingly excited about the potential of our pipeline ...

Leqembi, along with rare disease and depression treatments, helped offset a year-over-year decline in revenue for the company ...

Biogen Inc. is now projecting a better-than-expected 2024 as the company continues to see an uptick in sales from Leqembi, ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug ...

Even though Biogen raised earnings guidance, the company still has “some potentially concerning signals” in its base business ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi during the third quarter 2024, in conjunction with their partner Biogen's ...

TD Cowen analyst Phil Nadeau maintained a Buy rating on Biogen (BIIB – Research Report) yesterday and set a price target of $275.00. Phil ...

Biogen raised its annual profit forecast on Wednesday, as new treatments and cost-cutting measures offset declining sales of its multiple sclerosis drugs.